Payment overview · 2025
General Payments
$1,221.68
38 reported records · 16 companies
Healthcare provider profile · identity verified
George Carr Fareed, MD
Allopathic & Osteopathic Physicians|General Practice · BRAWLEY, CA · NPI 1720074313
Verified facts
What the public records show
CMS Open Payments records show George Carr Fareed, MD received $1,221.68 in general payments during 2025 across 38 reported records.
Integra LifeSciences Corporation accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Cabenuva, Dovato, Farxiga, Ozempic, Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Farxiga by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DELSTRIGO as an associated drug or biological on 864 records involving 608 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Delstrigo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rexulti by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABENUVA as an associated drug or biological on 13941 records involving 3305 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Cabenuva by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $267.84 | 21.9% | 3 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $254.78 | 20.9% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $173.52 | 14.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $162.61 | 13.3% | 6 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $65.36 | 5.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.13 | 3.9% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $46.14 | 3.8% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $43.52 | 3.6% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $32.17 | 2.6% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $30.84 | 2.5% | 1 | 2025 |
| BSN Medical Inc | Unresolved — no canonical attribution shown | $25.28 | 2.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.85 | 1.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.51 | 1.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.12 | 1.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.68 | 1.1% | 1 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $7.33 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $953.84 | 35 |
| Long term medical supply or device loan | $267.84 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $160.41 | 3 | 2025 |
Source payment records
|
|||||
| MicroMatrix Normalized: micromatrix |
Device | Integra LifeSciences Corporation | $146.02 | 2 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $132.14 | 5 | 2025 |
Source payment records
|
|||||
| Cytal Normalized: cytal |
Device | Integra LifeSciences Corporation | $121.82 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $116.88 | 3 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $114.31 | 5 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $65.36 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $47.13 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $46.14 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $43.52 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $32.17 | 1 | 2025 |
Source payment records
|
|||||
| AQUACEL AG+ Normalized: aquacel ag |
Device | ConvaTec Inc. | $30.84 | 1 | 2025 |
Source payment records
|
|||||
| SPECIALIST Normalized: specialist |
Device | BSN Medical Inc | $25.28 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.04 | 1 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.11 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $8.33 | 1 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $7.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CABENUVA cabenuva |
2025 | Cabenuva | 2024 | 51 | exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 62 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 104 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
104 | 28 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | DELSTRIGO open payments reported associated product |
CMS Open Payments — General Payments 864 supporting records · 608 recipient NPIs · example record 1237993240 |
Delstrigo · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | CABENUVA open payments reported associated product |
CMS Open Payments — General Payments 13941 supporting records · 3305 recipient NPIs · example record 1189508908 |
Cabenuva · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 642 | 179 |
| Amlodipine Besylate | Amlodipine Besylate | 456 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 444 | 108 |
| Metformin Hcl | Metformin Hcl | 412 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 354 | 86 |
| Gabapentin | Gabapentin | 345 | 86 |
| Losartan Potassium | Losartan Potassium | 342 | 90 |
| Omeprazole | Omeprazole | 317 | 96 |
| Eliquis | Apixaban | 306 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 296 | 70 |
| Furosemide | Furosemide | 288 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 278 | 73 |
| Potassium Chloride | Potassium Chloride | 245 | 60 |
| Lisinopril | Lisinopril | 229 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 229 | 46 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 224 | 116 |
| Carvedilol | Carvedilol | 207 | 49 |
| Buspirone Hcl | Buspirone Hcl | 202 | 26 |
| Tramadol Hcl | Tramadol Hcl | 189 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 184 | 26 |
| Simvastatin | Simvastatin | 182 | 44 |
| Trazodone Hcl | Trazodone Hcl | 180 | 44 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 157 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 39 |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 152 | 18 |
| Montelukast Sodium | Montelukast Sodium | 149 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 147 | 42 |
| Memantine Hcl | Memantine Hcl | 145 | 37 |
| Famotidine | Famotidine | 142 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 137 | 30 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 133 | 108 |
| Fenofibrate | Fenofibrate,micronized | 133 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 131 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 32 |
| Xarelto | Rivaroxaban | 109 | 17 |
| Jardiance | Empagliflozin | 107 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 40 |
| Farxiga | Dapagliflozin Propanediol | 104 | 28 |
| Glimepiride | Glimepiride | 99 | 26 |
| Nifedipine Er | Nifedipine | 98 | 15 |
| Entresto | Sacubitril/Valsartan | 93 | 16 |
| Ibuprofen | Ibuprofen | 92 | 33 |
| Ozempic | Semaglutide | 92 | 17 |
| Lorazepam | Lorazepam | 88 | 25 |
| Allopurinol | Allopurinol | 87 | 21 |
| Alprazolam | Alprazolam | 87 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 86 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 84 | 23 |
| Sucralfate | Sucralfate | 81 | 21 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 77 | 37 |
| Mirtazapine | Mirtazapine | 77 | suppressed |
| Trulicity | Dulaglutide | 76 | 12 |
| Levetiracetam | Levetiracetam | 74 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 73 | 18 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 72 | suppressed |
| Vascepa | Icosapent Ethyl | 72 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 71 | suppressed |
| Levofloxacin | Levofloxacin | 70 | 50 |
| Fenofibrate | Fenofibrate | 67 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 66 | 16 |
| Lactulose | Lactulose | 66 | 14 |
| Alendronate Sodium | Alendronate Sodium | 63 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 20 |
| Dovato | Dolutegravir Sodium/Lamivudine | 62 | suppressed |
| Finasteride | Finasteride | 61 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 15 |
| Meloxicam | Meloxicam | 59 | 20 |
| Bumetanide | Bumetanide | 58 | 13 |
| Meclizine Hcl | Meclizine Hcl | 58 | 20 |
| Donepezil Hcl | Donepezil Hcl | 57 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 29 |
| Ibandronate Sodium | Ibandronate Sodium | 56 | 13 |
| Primidone | Primidone | 56 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 15 |
| Celecoxib | Celecoxib | 53 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 51 | suppressed |
| Cabenuva | Cabotegravir/Rilpivirine | 51 | 12 |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | 16 |
| Sertraline Hcl | Sertraline Hcl | 50 | 16 |
| Tradjenta | Linagliptin | 50 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 25 |
| Tresiba Flextouch U-200 | Insulin Degludec | 48 | suppressed |
| Ezetimibe | Ezetimibe | 46 | 11 |
| Rybelsus | Semaglutide | 45 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 44 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 31 |
| Azithromycin | Azithromycin | 43 | 34 |
| Baclofen | Baclofen | 42 | suppressed |
| Pregabalin | Pregabalin | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 40 | 16 |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 39 | suppressed |
| Prednisone | Prednisone | 39 | 29 |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 36 | suppressed |
| Movantik | Naloxegol Oxalate | 36 | suppressed |
| Mupirocin | Mupirocin | 36 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Spironolactone | Spironolactone | 34 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 30 |
| Irbesartan | Irbesartan | 32 | suppressed |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 30 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 28 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 27 | 27 |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Darunavir | Darunavir | 27 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 27 | 14 |
| Xifaxan | Rifaximin | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 12 |
| Icosapent Ethyl | Icosapent Ethyl | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 25 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 24 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 22 | suppressed |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Restasis | Cyclosporine | 22 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 22 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 21 | 13 |
| Methimazole | Methimazole | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 12 |
| Diazepam | Diazepam | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Rexulti | Brexpiprazole | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Dexamethasone | Dexamethasone | 16 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 16 | suppressed |
| Misoprostol | Misoprostol | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Acarbose | Acarbose | 15 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 15 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Delstrigo | Doravirine/Lamivu/Tenofov Diso | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Tivicay | Dolutegravir Sodium | 11 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 11 | suppressed |
| Vienva | Levonorgestrel/Ethin.Estradiol | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,221.68 · 38 records | Integra LifeSciences Corporation | ACCRUFER, AIRSUPRA, APRETUDE, AQUACEL AG+, CABENUVA, CeQur Simplicity, Cytal, DOVATO, Da Vinci Surgical System, FARXIGA, Korlym, MicroMatrix, OTEZLA, Ozempic, PIFELTRO, RECORLEV, REPATHA, REXULTI, SPECIALIST, Senza, VOQUEZNA, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Cabenuva play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error